GEN Exclusives

More »

GEN News Highlights

More »
Oct 19, 2011

Arsanis Wins €1.2M for Research on Antibody Against Hospital-Acquired Infections

  • Arsanis Biosciences won a grant from the Austrian Research Promotion Agency (Forschungs-Förderungs-Gesellschaft; FFG) toward development of monoclonal antibody therapeutics against hospital-acquired or nosocomial infections. Arsanis will receive €1.19 million ($1.64 million) during the first year of its four-year research program, with the company expecting additional funding over the next three years to bring the total to €8.75 million (just over $12 million)—reflecting up to 70% of the research program’s total budget of €12.5 million ($17.24 million).

    The FFG grant will support discovery activities of several antibody projects and the preclinical and early clinical development of one lead program. Arsanis won funding in 2010 from a syndicate of U.S.-based venture firms OrbiMed Advisors, Polaris Venture Partners, and SV Life Sciences.

    “Arsanis is building a broad portfolio of anti-infective antibodies, several of which target nosocomial bacterial infections,” states Eszter Nagy, M.D., Ph.D., Arsanis’ co-founder and CSO.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?